Metoprolol Stada (Metoprolol Tartrate)

Metoprolol Tartrate selectively blocks β1‑adrenergic receptors in the heart. By preventing adrenaline and noradrenaline from binding, it reduces heart rate, myocardial contractility, and cardiac output, leading to lower blood pressure and decreased oxygen demand by the heart muscle.

The appropriate dose of Metoprolol Stada is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Metoprolol Tartrate in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Healthcare providers should weigh potential benefits against possible risks before prescribing to pregnant or nursing women.

To place an order, submit an enquiry on the Metoprolol Stada product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoprolol is a cardio‑selective (β1‑selective) blocker, offering a lower risk of bronchospasm compared with non‑selective agents such as propranolol. It is commonly chosen for hypertension, angina and heart‑failure management, whereas other beta blockers may be preferred for arrhythmia control or migraine prophylaxis.

Metoprolol Stada tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Metoprolol Stada is taken orally, usually with a glass of water. It can be taken with or without food, but the dose should be swallowed whole and not crushed or chewed unless the prescriber advises otherwise.

Serious adverse events include severe bradycardia, heart block, marked hypotension, bronchospasm in patients with reactive airway disease, and allergic reactions such as rash or angioedema. Patients should seek immediate medical attention if they experience fainting, rapid weight gain, or worsening shortness of breath.

Metoprolol Stada is contraindicated in patients with severe sinus bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, cardiogenic shock, and those with known hypersensitivity to metoprolol or any excipients. Caution is also advised for individuals with uncontrolled asthma or severe chronic obstructive pulmonary disease.